Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert-Jan Creemers

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair AnalysisJonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.
Journal of Geriatric Oncology|April 3, 2026
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort studyJoosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, et al.
The New England Journal of Medicine|November 9, 2007
Chemotherapy plus involved-field radiation in early-stage Hodgkin's diseaseChristophe Fermé, Houchingue Eghbali, Jacobus H Meerwaldt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2019
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP StudyCharlotte I Stroes, Sandor Schokker, Aafke Creemers, et al.
Genome Medicine|August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYDJonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U studyJonathan E Knikman, Mirjam de With, Niels Heersche, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Journal of Cancer Survivorship : Research and Practice|April 11, 2021
Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancerLente L Kroon, Janneke van Roij, Ida J Korfage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 24, 2019
The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysisTara M Mackay, F Jasmijn Smits, Daphne Roos, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair AnalysisJonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.
Journal of Geriatric Oncology|April 3, 2026
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort studyJoosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, et al.
The New England Journal of Medicine|November 9, 2007
Chemotherapy plus involved-field radiation in early-stage Hodgkin's diseaseChristophe Fermé, Houchingue Eghbali, Jacobus H Meerwaldt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2019
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP StudyCharlotte I Stroes, Sandor Schokker, Aafke Creemers, et al.
Genome Medicine|August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYDJonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U studyJonathan E Knikman, Mirjam de With, Niels Heersche, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Journal of Cancer Survivorship : Research and Practice|April 11, 2021
Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancerLente L Kroon, Janneke van Roij, Ida J Korfage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|August 24, 2019
The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysisTara M Mackay, F Jasmijn Smits, Daphne Roos, et al.
Pageof 10